📅 PUBMED DAILY TRIAGE — 2026-05-12

Window: 2026-05-11T09:00:00Z → 2026-05-12T09:00:00Z (CRDT) Topics scanned: 10 | Candidates evaluated: ~87 | Articles classified: 11 High priority: 2 | Standard: 9 | Low/archive: 7 | Unsolicited finds: 0 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Cardiovascular-Metabolic: GLP-1, SGLT2, Cardiometabolic Risk

TR-2026-05-12-001 / PMID 42115753 · GLP-1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta-Analysis · 9/10 🟢 NEAR_TERM_IMPLEMENTABLE

Meta-analysis of 9 RCTs + 2 observational studies (n=10,175 adolescents) found GLP-1 RAs are not associated with increased suicide risk and may actually reduce suicidal ideation (RR 0.73, p=0.046, I²=0%) — directly resolves a major prescriber concern and directly actionable for clinical practice. Diabetes Obes Metab. 2026.

Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

TR-2026-05-12-002 / PMID 42115611 · A specific stem cell program and CD112 immunological axis dysfunctions underpinning monosomy 7-associated myeloid neoplasms · 8/10 🟠 NOVEL_TREATMENT

First disclosure of a dysfunctional TIGIT-PVRIG-DNAM1/CD112 immunological axis in monosomy 7 myeloid neoplasms; blocking TIGIT/PVRIG ex vivo restored NK cell cytolysis against leukemic cells — opening checkpoint blockade as a new therapeutic strategy for an otherwise undruggable, poor-prognosis cytogenetic subset. Signal Transduct Target Ther. 2026. IF~40.

🟢⚪ STANDARD (5–7) — Top by Topic

Precision Oncology & Genomic Medicine

• TR-2026-05-12-003 / PMID 42115771 · Multi-omics profiling reveals TME characteristics linked to immunotherapy response and prognosis in NSCLC · 7/10 · Precision Oncology
  • ZNF683+ CD8+ T cells as immunotherapy biomarker; ZNFRS prognostic score; anti-SPP1 + anti-PD-1 combo enhanced efficacy in vivo. NPJ Precis Oncol. 2026.

Cardiovascular-Metabolic: GLP-1, SGLT2, Cardiometabolic Risk

• TR-2026-05-12-004 / PMID 42115761 · SGLT2 and DPP-4 inhibitors not associated with acute pancreatitis — Korean nationwide study (n=7,219) · 7/10 · Drug Development
  • Case-case-time-control + nested case-control design; neither SGLT2i nor DPP-4i raised pancreatitis risk (aOR 0.84–1.05 for SGLT2i). Diabetes Obes Metab. 2026.

Aging, Longevity & Population Health

• TR-2026-05-12-005 / PMID 42114133 · Stroke survivors' long-term home care use — South London registry, n=7,885, up to 15 years · 6/10 · Public Health
  • 75% used home care; informal care dominated at 83–87%; unmet ADL needs rose from 12% to 17% over 15 years; ethnic/socioeconomic disparities documented. Eur Stroke J. 2026.

Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)

• TR-2026-05-12-006 / PMID 42115377 · Early-onset colorectal cancer: comprehensive review reframing hypotheses · 6/10 · Early Detection
  • EOCRC rising globally; age-based screening causes systematic delay; liquid biopsy and multi-omics not yet translated to EOCRC-specific tools; outlines research priorities. Int J Colorectal Dis. 2026.
• TR-2026-05-12-007 / PMID 42110799 · Novel microfluidic system for pancreatic CTC isolation — Plectin-1 + EpCAM dual marker, 91.3% recovery · 6/10 · Early Detection
  • 3D-printed immunomagnetic platform captures PDAC CTCs in <1 min from blood; dual EpCAM+Plectin-1 outperforms single-marker (91.3% vs 47–80%). ACS Omega. 2026. (PMC open access)

AI/ML in Clinical Diagnostics & Imaging

• TR-2026-05-12-008 / PMID 42115786 · Unified deep learning for cytology instance segmentation across Papanicolaou, Feulgen, AgNOR stains · 6/10 · Diagnostics
  • Single Mask2Former model matches/exceeds stain-specific models; superior boundary precision (AP75) on multi-stain combined dataset. Cytopathology. 2026.

Novel Therapeutics: Immunotherapy, CAR-T, Targeted Therapy

• TR-2026-05-12-009 / PMID 42115674 · Patient-reported outcomes: ide-cel vs cilta-cel CAR-T in relapsed/refractory multiple myeloma (n=99) · 6/10 · Treatment Innovation
  • First real-world PRO comparison: both products show similar HRQOL trajectories (worse pre-D7, improved post-D7); differences in cognitive function (post-D7) and social well-being (pre-D7). Bone Marrow Transplant. 2026.
• TR-2026-05-12-010 / PMID 42115783 · Bispecific anti-FITC × anti-CD3 T-cell engager enables AML cell lysis via fluoresceinated adaptors · 5/10 · Treatment Innovation (non-human cap)
  • Versatile switchable TCE platform targeting CD33 + CD117 in AML; NSG mouse efficacy comparable to adaptor-CAR-T. Mol Cancer Ther. 2026.

Rare Diseases with High Unmet Need

• TR-2026-05-12-011 / PMID 42115623 · Neuregulin-1 facilitates myelin regeneration via microglia in chronic demyelination (progressive MS mouse model) · 5/10 · Drug Development (non-human cap)
  • NRG-1 restoration supports microglia-driven remyelination by enabling cholesterol recycling/efflux and myelin debris clearance; novel target for progressive MS. Nat Commun. 2026.

💡 UNSOLICITED FINDS

None today. All classified articles matched active watchlist topics.

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 5 articles (42115611, 42115674, 42115783, 42115623, 42115771)
• Drug Development: 3 articles (42115753, 42115761, 42115623)
• Early Detection: 2 articles (42115377, 42110799)
• Diagnostics: 1 article (42115786)
• Public Health: 2 articles (42114133, 42115761)
• Genomics/Precision Medicine: 1 article (42115771)

By evidence maturity:

• Validated: 4 (42115753, 42115761, 42114133, 42115786)
• Exploratory: 7 (42115611, 42115771, 42115377, 42110799, 42115674, 42115783, 42115623)
• Potentially Practice-Changing: 0

By watchlist topic — reviewed / kept / highest score:

By source type:

• Peer-reviewed: 11 | Preprint: 0

Topics with zero 8+ articles this run: Early cancer detection, AI/ML diagnostics, Precision oncology, Novel therapeutics, Aging/longevity, Rare diseases, Sentinel

🔧 RUN NOTES

• CRDT boundary: PMID 42110799 has entrez timestamp 2026-05-11T06:46Z (before nominal 09:00 window start). Included per date-level CRDT filter (all of 2026/05/11 in scope). Not in prior state fingerprints — confirmed new.
• CBC/ML hematology: 20th+ consecutive sparse window. 4 results total; 1 already emitted; 3 remaining reviewed at title-only level (all scored ≤3). Topic query refinement recommended for next run.
• AI/ML diagnostics: 209 results; top 10 reviewed. High noise-to-signal ratio — many results matched incidentally on keyword "imaging" or "pathology" without being directly on-target diagnostic AI. Consider query tightening.
• Novel therapeutics cap hit (141 results); significant overlap with hematologic malignancies topic.
• Sentinel scan: 1,020 broad results; PMID 42108508 already emitted from prior state; 9 remaining candidates reviewed; none reached STANDARD threshold.
• No rolling 7-day CBC/ML hematology data available — pattern has been consistently empty for 20+ runs.
• Alert budget: 2 HIGH articles → 2 Telegram alerts sent (TR-2026-05-12-001, TR-2026-05-12-002). Budget not exceeded.